Experts Discuss Innovation in Epilepsy, Ucb . Conference

Epilepsy is one of the most common neurological diseases affecting all agesAbout 50-70 million people in the world participate in it, of which 500 thousand are in Italy alone. This disorder is more common in childhood and old age, and thus can interfere with normal activities at crucial stages of life. Scientific research has made tremendous progress in diagnosis and treatment, In the past 15-20 years the number of available drugs has increased significantly, but there is still a lot to do, also considering the fact that about 30% of patients still have seizures that are not fully controlled by treatment and that more than 30% of people with epilepsy have drug-resistant forms of the disease. . These issues were discussed during ‘bright contacts‘, the conference organized by Ucb, today and tomorrow in Milan, with the aim of shedding light on the pathology and treatment options available, and deepening the contribution of innovation in an absolute technological and health sense.

The clinical status of a patient with epilepsy – make a note – actually has an enormous social and economic impact Correct diagnostic-therapeutic management is able to significantly improve all health and well-being outcomes of the patient It can reduce the impact of epilepsy on school/educational, social, work, emotional, and recreational activities. About two-thirds of people with epilepsy actually get moderate control of their manifestations with anti-epileptic drugs. Therefore, research and innovation play a critical role in ensuring further progress in the understanding and management of the various forms of epilepsy.

Organized by Ucb – a company for more than 30 years committed to improving the lives of people with epilepsy, through drug research and development – the conference wanted to shed light on the treatment and disease options available by deepening the contribution of innovation to the ultimate, technological, and healthy meaning. The event was also an opportunity for discussion between doctors at national and international levels To increase knowledge and awareness of recent acquisitions related to epilepsy and the latest data on the latest anti-seizure drugs.

UCB – Details of the note – is constantly collecting and publishing new data from studies dedicated to its combination of treatments: brivaracetam, lacosamide, levetiracetam, and midazolam nasal spray (currently FDA-approved). Also in 2022, new real-world evidence publications confirm the value of UCB’s commitment to people with epilepsy and their caregivers. Additionally, UCB’s recent confirmed acquisition of Zogenix signals an effort to make a difference for the company in rare and more difficult to treat forms of epilepsy, such as Dravet syndrome.

From a recent study conducted by the Center for Cerismas (Center for Research and Studies in Health Administration) of the Catholic University of the Sacred Heart with the support of Ucb Pharma, it appears that The importance of responding to the individual needs of a person with epilepsy also with organizational and technically innovative solutions For services that are truly within the reach of the individual. For this reason, the conference also touched upon the need for innovation from an organizational point of view, starting with the performance of the NHS itself, and from a technological point of view.

The Covid pandemic has shown, in this regard, even more clearly The need to introduce telemedicine in the management of epilepsyAs long as there are treatments that meet the characteristics of simplicity, speed and safety and are therefore more suitable for use in telemedicine. Furthermore, televisions can be a valuable tool for conducting examinations, and thus for monitoring seizure progression, evaluating adverse drug events, and making therapeutic changes. Finally, since epilepsy is an unpredictable pathology, it also needs the possibility Self-management by the patient which includes, for example, active self-monitoring with electronic notes on various devices Such as smartphones, tablets or computers, passive monitoring using wearable robotic devices to detect crises.

about this, UCB recently became the majority shareholder in Nile, an independent e-health company, born with the goal of facilitating the path of every person with epilepsy.. The Nile digital platform consists of an application for people with epilepsy, which allows them to continuously communicate with their care team, relieving the sense of uncertainty generated by the unpredictability of the disease, as well as a portal for healthcare professionals, through which they can have insight Comprehensive and immediate status of each person treated, guiding decisions to be made backed by data.

The other issue that witnessed the most involved experts was the case Real world guide, an essential tool from the perspective of developing personalized medicine, also useful for the purpose of optimizing pharmaceutical spending, and for all these reasons, an innovative tool for health governance. This approach, made possible by innovative communications and networking between different centers, can help improve knowledge of medical performance, generate new evidence and respond to unresolved clinical needs by offering clear advantages, such as longer follow-ups than those of trials. Standard, larger and more representative sample sizes.

“Ucb has developed a great deal of experience in the field of epilepsy and is well aware of the challenges facing people who suffer from it,” he explained. Federico Chinni, CEO of Ucb Italia. “We are convinced that it is necessary to continue on this ongoing path of innovation on different fronts, at the scientific, organizational, therapeutic and technological levels, to continue to improve treatment standards and, more generally, to respond increasingly to the unmet needs of people with epilepsy.”

Leave a Comment